Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than ...

The decision to advance prasinezumab to Phase III was based on results from the Phase IIb PADOVA trial, which demonstrated ...

Genentech, part of the Roche Group (OTCQX:RHHBY), said that a late-stage study testing Lunsumio, along with Polivy, showed ...

Shares of Roche drew increased retail attention Monday after the Swiss drugmaker said it would move its investigational ...

Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

The Swiss drugmaker said it was “encouraged” by the signs of effectiveness of the drug, developed by biotech Prothena, showed ...

Roche and Prothena are forging ahead to late-stage studies for their investigational Parkinson’s disease antibody ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

The commercial and clinical use of Elevidys was discontinued after two fatal cases of acute liver failure.

Basel: Roche has announced its decision to proceed with Phase III development of prasinezumab, an investigational ...